Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CNTY
CNTY logo

CNTY Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Century Casinos Inc (CNTY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.420
1 Day change
-1.39%
52 Week Range
2.850
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Century Casinos Inc (CNTY) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance is weak, with declining net income and EPS, and there are no strong positive catalysts or trading signals to support a buy decision. Additionally, technical indicators and options data do not suggest a strong bullish sentiment or immediate growth potential.

Technical Analysis

The MACD is slightly positive but contracting, indicating a lack of strong momentum. The RSI is neutral at 34.468, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level (S1: 1.441), but there is no indication of a reversal or breakout.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate minimal bearish sentiment, but the lack of significant call volume also suggests limited bullish activity. Implied volatility is high (175.56), but this does not necessarily indicate a favorable opportunity.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
5

Positive Catalysts

  • Gross margin increased by 2.01% YoY, showing slight operational improvement.

Neutral/Negative Catalysts

  • Net income dropped by -80.13% YoY, and EPS declined by -79.25% YoY in the latest quarter (2025/Q4). There are no recent news events or significant insider or hedge fund activity to support a bullish case. Congress trading data is also absent.

Financial Performance

In 2025/Q4, revenue increased marginally by 0.16% YoY to $137.99M, but net income dropped significantly to -$17.95M, and EPS fell to -0.61. The company's financials indicate declining profitability and weak growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for CNTY.

Wall Street analysts forecast CNTY stock price to rise
2 Analyst Rating
Wall Street analysts forecast CNTY stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.440
sliders
Low
4
Averages
4
High
4
Current: 1.440
sliders
Low
4
Averages
4
High
4
Piper Sandler
NULL
to
Overweight
upgrade
$2 -> $4
AI Analysis
2026-01-20
Reason
Piper Sandler
Price Target
$2 -> $4
AI Analysis
2026-01-20
upgrade
NULL
to
Overweight
Reason
Piper Sandler raised the firm's price target on Century Therapeutics to $4 from $2 and keeps an Overweight rating on the shares. The firm notes Century plans to submit an IND for CNTY-813 this year and report initial data in 2027. Piper estimates Century now hold pro forma cash of about $267M to fund operations into Q1 2029.
Clear Street
Bill Maughan
Buy
downgrade
$8
2026-01-08
Reason
Clear Street
Bill Maughan
Price Target
$8
2026-01-08
downgrade
Buy
Reason
Clear Street analyst Bill Maughan lowered the firm's price target on Century Therapeutics to $6.60 from $8 and keeps a Buy rating on the shares. The private placement brings the runway out to 1Q29, allowing for development of a fuller picture of the true potential of lead asset CNTY-813 before needing additional capital, the analyst tells investors in a research note. The firm added that it is reducing its price target on dilution from the raise, offset by increased pipeline likelihood of success and peak sales.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CNTY
Unlock Now

People Also Watch